FDA approves Roche breast cancer pill Wilserdly for advanced disease
The US Food and Drug Administration approved Roche's Wilserdly on 16 November for advanced breast cancer with ESR1 mutations, extending progression-free survival to 10 months.
Photo: STAT NewsKey points
The FDA approved Roche's Wilserdly for advanced breast cancer with ESR1 mutations, improving progression-free survival to 10 months.
The US Food and Drug Administration approved Roche's new breast cancer pill Wilserdly on 16 November, clearing the way for a medicine the drugmaker expects to change how the disease is treated. The approval covers use in combination with a targeted cancer therapy for locally advanced or metastatic breast cancer driven by a genetic mutation.
Approval details
Wilserdly, also known as giredestrant, is approved for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, based on results from the phase 3 evERA clinical trial. The trial was led by investigators at Dana-Farber Cancer Institute and funded by F. Hoffmann-La Roche Ltd. The drug is intended for patients whose cancer has recurred or progressed after prior therapy, the agency said on Monday. It is taken once a day until the disease worsens or the patient develops unacceptable toxic complications, and it comes with a warning label.
The approval marks an important advance for patients with estrogen receptor-positive, HER2-negative advanced breast cancer, the most common form of metastatic breast cancer. Approximately 70% of breast cancers are estrogen receptor-positive, and treatment options can become more limited when tumors develop resistance to endocrine therapies. In the evERA study, the combination of giredestrant and everolimus significantly improved progression-free survival compared with a standard-of-care combination of endocrine therapy and everolimus. The study enrolled 373 patients, approximately 55% of whom had mutations in the estrogen receptor gene.
Trial results
After a median follow-up of 18.6 months, patients whose tumors harbored an ESR1 mutation and received giredestrant plus everolimus experienced a median progression-free survival of 10 months, compared with 5.5 months among patients receiving the standard-of-care combination. This represented a 63% reduction in the risk of disease progression or death.
In the overall study population, including patients with and without ESR1 mutations, median progression-free survival was 8.8 months for patients receiving giredestrant plus everolimus, compared with 5.5 months for those receiving standard-of-care treatment, representing a 44% reduction in the risk of disease progression or death. Giredestrant is a next-generation selective estrogen receptor degrader and full antagonist. It works by binding to the estrogen receptor and promoting its degradation, preventing estrogen from stimulating cancer cell growth. Everolimus is a targeted therapy that inhibits mTOR, a protein involved in cell growth and survival.
Mechanism and next steps
As oncologists we are always looking for better and more effective treatments for patients with metastatic breast cancer, particularly when their disease progresses on endocrine therapies and CDK4/6 inhibitors, said Erica Mayer, MD, MPH, Director of Breast Cancer Clinical Research at Dana-Farber and principal investigator of the evERA study. Today's FDA approval of giredestrant gives patients an important new therapeutic option which substantially improves disease control while also providing the convenience of an all-oral regimen.
Initial findings from the evERA study were presented at the 2025 Congress of the European Society for Medical Oncology. The study results were subsequently published in the New England Journal of Medicine on October 1, 2026. Roche has said that Wilserdly could become its top-selling product ever. The approval provides a new option for some patients and a boost for the Swiss company. The FDA's decision on 16 November follows the agency's review of the evERA data. Patients with advanced breast cancer who have ESR1 mutations now have a new oral treatment option that improves disease control.
Frequently asked questions
What is Wilserdly?
Wilserdly, also known as giredestrant, is a next-generation selective estrogen receptor degrader. It binds to the estrogen receptor and promotes its degradation, preventing estrogen from stimulating cancer cell growth.
Who is eligible for Wilserdly?
Adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred or progressed after prior therapy.
How effective is Wilserdly?
In the evERA trial, patients with ESR1 mutations had median progression-free survival of 10 months versus 5.5 months with standard care, a 63% reduction in risk of progression or death.


